Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ixempra Bar Graphs Land Bristol-Myers Sales Aid In The Slammer

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA notice of violation letter to the company says its promotion material, which relies heavily on subgroup analyses of secondary endpoints, makes unsubstantiated efficacy claims and broadens the indication for the breast cancer drug.

You may also be interested in...

FDA Cleared Ixempra Despite Doubts Over Chance Of Showing Survival Benefit

Doubts about the likelihood that the improvement in progression-free survival seen in a pivotal trial of Bristol-Myers Squibb's Ixempra (ixabepilone) will translate to an overall survival advantage could add to the controversy over the appropriateness of PFS as a surrogate for survival in metastatic breast cancer.

Supreme Court Seems To Support Government’s Later Dismissal Of False Claims Act Cases

Justices cite changing circumstances, constitutional concerns in preventing government from seeking dismissal of a case in which it initially declined to intervene. They also question whether government should intervene before moving to dismiss.

Battle Over Patents And Drug Pricing Engulfs FDA And USPTO

President Biden and Congress are pressuring the agencies to change patent policies so brand manufacturers cannot delay generic and biosimilar competition to keep monopoly prices. Timeline shows how they have responded to these demands.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts